Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy

被引:128
作者
Kissel, JT
McDermott, MP
Mendell, JR
King, WM
Pandya, S
Griggs, RC
Tawil, R
Cos, L
Langsam, A
Martens, B
Brower, C
Herr, BE
Figlewicz, D
Forrester, J
Downing, K
Holloway, RG
Hubble, J
Kolassa, J
机构
[1] Ohio State Univ, Ctr Med, Div Neuromuscular Dis, Dept Neurol, Columbus, OH 43210 USA
[2] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med & Dent, Wayne C Gorrell Jr Mol Biol Lab, Rochester, NY 14642 USA
[4] Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA
关键词
D O I
10.1212/WNL.57.8.1434
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background/Objectives: Animal and human studies suggest that beta (2)-adrenergic agonists exert anabolic effects on muscles, inducing and preventing atrophy after a variety of insults. Based on data from an open-label trial of albuterol in 15 patients with facioscapulohumeral dystrophy (FSHD), the authors conducted a randomized, double-blind, placebo-controlled trial of sustained-release albuterol in this disease. Methods: Ninety patients were randomized to three groups: placebo; 8.0 mg albuterol twice daily; or 16.0 mg albuterol twice daily. Patients were treated for 1 year with assessments at baseline and weeks 13, 26, and 52. The primary outcome was the 52-week change in global strength by maximum voluntary isometric contraction testing (MVICT). Secondary outcomes included changes at 52 weeks in strength by manual muscle testing (MMT), grip strength, functional testing, and muscle mass assessed by dual energy x-ray absorptiometry (DEXA). Results: Eighty-four patients completed the study. The mean changes in composite MVICT scores were not significantly different between the groups (mean +/- SD: placebo 0.20 +/- 0.91; low dose -0.04 +/- 0.84; high dose 0.08 +/- 0.98). Similarly, there were no differences in the mean MMT change (placebo 0.04 +/- 0.16; low dose -0.03 +/- 0.13; high dose 0.00 +/- 0.15). Grip improved in both treatment groups compared to placebo (placebo -0.53 +/- 4.13, low dose +1.90 +/- 3.34 [p = 0.02], high dose +1.70 +/- 4.13 [p = 0.03]). The high-dose group had a significant increase in lean mass by DEXA (+1.57 +/- 1.71 kg) compared to placebo (0.25 +/- 2.24; p = 0.007). Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness. Conclusions: Although albuterol did not improve global strength or function in patients with FSHD, it did increase muscle mass and improve some measures of strength.
引用
收藏
页码:1434 / 1440
页数:7
相关论文
共 25 条
[1]  
CARUSO JF, 1995, MED SCI SPORT EXER, V27, P1471
[2]   Effects of clenbuterol on contractile and biochemical properties of skeletal muscle [J].
Dodd, SL ;
Powers, SK ;
Vrabas, IS ;
Criswell, D ;
Stetson, S ;
Hussain, R .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1996, 28 (06) :669-676
[3]   Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice [J].
DupontVersteegden, EE .
JOURNAL OF APPLIED PHYSIOLOGY, 1996, 80 (03) :734-741
[4]   Molecular genetics of facioscapulohumeral muscular dystrophy (FSHD) [J].
Fisher, J ;
Upadhyaya, M .
NEUROMUSCULAR DISORDERS, 1997, 7 (01) :55-62
[5]   VALIDATION OF BODY-COMPOSITION BY DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA) [J].
HAARBO, J ;
GOTFREDSEN, A ;
HASSAGER, C ;
CHRISTIANSEN, C .
CLINICAL PHYSIOLOGY, 1991, 11 (04) :331-341
[6]   Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol [J].
Hayes, A ;
Williams, DA .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 157 (02) :122-128
[7]   Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming [J].
Hayes, A ;
Williams, DA .
JOURNAL OF APPLIED PHYSIOLOGY, 1997, 82 (02) :435-439
[8]   The β-adrenoceptor [J].
Johnson, M .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (05) :S146-S153
[9]   Facioscapulohumeral dystrophy [J].
Kissel, JT .
SEMINARS IN NEUROLOGY, 1999, 19 (01) :35-43
[10]   Pilot trial of albuterol in facioscapulohumeral muscular dystrophy [J].
Kissel, JT ;
McDermott, MP ;
Natarajan, R ;
Mendell, JR ;
Pandya, S ;
King, WM ;
Griggs, RC ;
Tawil, R .
NEUROLOGY, 1998, 50 (05) :1402-1406